{"disease":{"id":"neovascular-age-related-macular-degeneration","name":"neovascular age related macular degeneration"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04847895","title":"Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications","phase":"","overall_status":"COMPLETED","enrollment_count":5500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04985487","title":"Regulatory Post-Marketing Surveillance Study for Brolucizumab","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06929143","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04935411","title":"Russian Registry of Patients With nAMD","phase":"","overall_status":"TERMINATED","enrollment_count":2665,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06075147","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06021366","title":"Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study","phase":"","overall_status":"COMPLETED","enrollment_count":2089,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06184360","title":"Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)","phase":"","overall_status":"COMPLETED","enrollment_count":2079,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02307682","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1775,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT06495203","title":"A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO","phase":"","overall_status":"COMPLETED","enrollment_count":1350,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03577899","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1157,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03630952","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1157,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06491914","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1118,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02434328","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1048,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT04777201","title":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1036,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04423718","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1011,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT06439576","title":"Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03683251","title":"Extension Study for the Port Delivery System With Ranibizumab (Portal)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04757636","title":"OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":998,"lead_sponsor_name":"Opthea Limited","has_results":true},{"nct_id":"NCT04757610","title":"OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":986,"lead_sponsor_name":"Opthea Limited","has_results":true},{"nct_id":"NCT07516132","title":"Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":false},{"nct_id":"NCT06680817","title":"A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06495918","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":825,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":false},{"nct_id":"NCT07275840","title":"A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Innovent Biologics Technology Limited (Shanghai R&D Center)","has_results":false},{"nct_id":"NCT06890026","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06723288","title":"A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)","phase":"","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01958918","title":"Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01780935","title":"Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":671,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05972473","title":"A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT05904028","title":"Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Jaeb Center for Health Research","has_results":false},{"nct_id":"NCT04690556","title":"Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Lupin Ltd.","has_results":true},{"nct_id":"NCT04270747","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04480463","title":"A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Sam Chun Dang Pharm. Co. Ltd.","has_results":true},{"nct_id":"NCT04543331","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02418754","title":"Study of Intravitreal REGN2176-3 in Participants With Neovascular (\"Wet\") Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":505,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04662944","title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","phase":"","overall_status":"COMPLETED","enrollment_count":494,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05439629","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":488,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT04864834","title":"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":485,"lead_sponsor_name":"Sandoz","has_results":true},{"nct_id":"NCT04657289","title":"A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":451,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04450329","title":"A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":449,"lead_sponsor_name":"Samsung Bioepis Co., Ltd.","has_results":true},{"nct_id":"NCT06699914","title":"A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)","phase":"","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04522167","title":"Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":434,"lead_sponsor_name":"Bioeq GmbH","has_results":true},{"nct_id":"NCT03677934","title":"A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":415,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06178770","title":"Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":414,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06190093","title":"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Outlook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04047472","title":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05202587","title":"The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT","phase":"","overall_status":"COMPLETED","enrollment_count":386,"lead_sponsor_name":"Notal Vision Inc.","has_results":false},{"nct_id":"NCT03345082","title":"A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Opthea Limited","has_results":false},{"nct_id":"NCT02713204","title":"Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":365,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}